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REVIEW
Abstract: The mechanisms underlying the pathophysiology of severe psychiatric illnesses
are complex, involving multiple neuronal and neurochemical pathways. A growing body of
evidence indicates that alterations in hypothalamic–pituitary–adrenal (HPA) axis function
may be a trait marker in both mood disorders and psychosis, and may exert significant causal
and exacerbating effects on symptoms and neurocognition. At present, however, no available
treatments preferentially target HPA axis abnormalities, although many drugs do increase
feedback-regulation of the HPA axis at the level of the glucocorticoid receptor (GR). This
action may in part underpin their therapeutic efficacy. Therapeutic interventions directly
targeted at GR function may therefore have clinical benefit. The present review examines the
current literature for the clinical utility of GR antagonists (specifically mifepristone) in mood
disorders and psychosis. At present, most studies are at the “proof-of-concept” stage, although
the results of preliminary, randomized, controlled trials are encouraging. The optimum strategy
for the clinical application of GR antagonists is yet to be established, their potential role as
first-line or adjunctive treatments being unclear. The therapeutic utility of such drugs will
become known within the next few years following the results of larger clinical trials currently
underway.
Keywords: mifepristone, RU486, glucocorticoid receptor, cortisol, mood disorders, psychosis,
treatment
Introduction
Overview
Dysfunction of the hypothalamic–pituitary–adrenal (HPA) axis has long been
implicated in the pathogenesis and etiology of severe psychiatric illness. Studies
have found evidence of reduced glucocorticoid receptor (GR) mRNA expression in
post-mortem brain tissue samples from patients with mood disorders and psychosis
(Knable et al 2001; Webster et al 2002; Lopez et al 2003). Many antidepressant
drugs increase GR binding and/or number in brain tissue, suggesting that GR
regulation may be one aspect of the therapeutic mechanism of action of antidepressants
(and mood stabilizers), and the ability of a drug to regulate GR number may be a
good predictor of therapeutic efficacy in patients with hypercortisolemia (McQuade
and Young 2000). No drugs primarily or preferentially target the GR for use in
psychiatry, although several are at present being examined for this purpose. The
present review examines the current literature and proof-of-concept evidence for
the clinical utility of GR antagonists (specifically mifepristone) in mood disorders
and psychosis.
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Search strategy
In order to include other antiglucocorticoid agents that
specifically target the GR, the terms (“mifepristone” or “RU
486” or “RU 38486” or “ORG 34850”’ or “ORG 34116” or
“ORG 34517”) were used in the initial search and combined
with the terms (“mood disorders” or “psychosis” or
“depression” or “bipolar disorder” or “schizophrenia”). The
following databases were searched electronically: EMBASE
(1980 to present), Medline (1966 to present), CINAHL
(1982 to present), PsycINFO (1887 to present), and ISI Web
of Science (1981 to present). Citation lists of relevant studies
and reviews were checked for other relevant trials.
Background
The hypothalamic–pituitary–adrenal
(HPA) axis
One of the major hormonal systems activated during stress
is the HPA axis. Neurones in the paraventricular nucleus
(PVN) of the hypothalamus secrete corticotrophin-releasing
hormone (CRH) which is transported via the hypothalamo-
pituitary portal circulation to the anterior pituitary where
adrenocorticotropic hormone (ACTH) is secreted through
stimulation of pituitary corticotrophs. ACTH then enters the
peripheral circulation and stimulates the adrenal cortex to
secrete glucocorticoids: corticosterone in rats, and cortisol
in humans.
Cortisol is essential for life. It is involved in the
maintenance of glucose production from protein, facilitates
fat metabolism, supports responsiveness of the vascular tree,
modulates central nervous system function, and profoundly
affects the immune system (Berne and Levy 1998).
Importantly, it is a major regulator of the physiological stress
response, through a negative feedback mechanism via
corticosteroid receptors. Two distinct corticosteroid receptor
subtypes have been identified: the mineralocorticoid
receptor (MR; Type I) and the glucocorticoid receptor (GR;
Type II). Both receptor types have been implicated in
mediating glucocorticoid feedback (Reul and de Kloet
1985), but there are several differences in the distribution,
occupancy, and binding properties of the two receptors that
affect their physiological role.
The MR is highly expressed in the limbic system whereas
the GR is ubiquitous, being present in both subcortical and
cortical structures, with a preferential distribution in the
prefrontal cortex (Patel et al 2000). Glucocorticoids bind to
the MR with 6–10 times higher affinity than to GR (de Kloet
et al 1999). Consequently, at basal levels near complete
occupation (~90%) of MRs occurs. GRs, however, are little
occupied at this point (~10%), and only during times of
high cortisol secretion, such as the circadian peak or during
stress, do MRs become saturated and GR occupancy
increases (to ~67%–74%) (Reul and de Kloet 1985). GR
function is therefore critical in the regulation of the HPA
axis at times of glucocorticoid excess and it is now
recognized that disruption of this self-regulating system may
be a major factor in the pathophysiology of mood disorders
and psychosis.
The HPA axis in mood disorders and
psychosis
The first observations of an elevation in basal cortisol levels
in patients with depression were made almost half a century
ago by Board and colleagues, and these observations have
been repeatedly replicated (Board et al 1956; Gibbons 1964).
It should be noted that the extent of HPA axis dysfunction
differs by severity and subtype of depression. For example,
a recent study found no evidence of hypercortisolism in
women with major depression from a community-based
setting (Strickland et al 2002), while pronounced HPA axis
dysfunction has been described in depressed subjects with
psychotic features (Posener et al 2000). The presence of
psychosis may be related to hypercortisolism independently
of mood symptoms (Christie et al 1986). Hypercortisolism
has also been recognized in symptomatic schizophrenic
patients (Ritsner et al 2004; Ryan et al 2004).
Improvements in the methodology utilized has overcome
some of the complexities surrounding the profiling of HPA
axis dysfunction, revealing alterations in the diurnal pattern
of cortisol secretion in depression (Deuschle et al 1997;
Posener et al 2000), while employing less precise techniques
such as total 24-hour cortisol output can fail to detect
dysfunction (Brouwer et al 2005). Similarly, the measure-
ment of the molar ratio of cortisol to other adrenal steroids
can reveal differences – in the absence of hypercortisolism
per se – in moderately depressed, non-psychotic outpatients
(Young et al 2002). The most sensitive tests of HPA axis
function, however, are “activating” tests, whereby
neuroendocrine responses are measured following pharma-
cological challenge. These are preferred not only because of
their increased sensitivity, but because they elucidate
functional changes in the HPA axis at the receptor level.
The GR agonist dexamethasone has been used widely
to examine HPA axis negative feedback integrity (Rush et
al 1996). An abnormal (nonsuppressed) cortisol responseNeuropsychiatric Disease and Treatment 2006:2(1) 35
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to dexamethasone administration has been described in
schizophrenia (Castro et al 1983; Muck-Seler et al 1999)
(but also see Ismail et al 1998) and mood disorders (Rush
et al 1996), and may be exacerbated by psychotic features
(Duval et al 2000). The combined dexamethasone–
corticotrophin-releasing hormone (dex–CRH) test is also
abnormal in bipolar patients during relapse and recovery
(Schmider et al 1995; Rybakowski and Twardowska 1999;
Watson et al 2004). Furthermore, GR abnormalities have
been observed in post-mortem studies which show evidence
of reduced GR mRNA expression in post-mortem brain
tissue samples from patients with bipolar disorder and
schizophrenia (Knable et al 2001; Webster et al 2002; Lopez
et al 2003).
Consequences of HPA axis
dysregulation and implications for
treatment
Pronounced neurocognitive dysfunction is frequently
described in mood disorder (Porter et al 2003; Thompson
et al 2005); this may be worse in patients with psychotic
features (Fleming et al 2004). In schizophrenia, the
symptomatic clinical profile of the illness is complex and
diverse, but neurocognitive impairment is consistently
reported and some authors have argued that such
impairments may be the cardinal feature of the illness
(Elvevag and Goldberg 2000).
Elevated levels of corticosteroids are known to impair
learning and memory. This has been demonstrated by acute
(Lupien and McEwen 1997; Modell et al 1997) and
subchronic (Young et al 1999) administration of exogenous
corticosteroids in healthy volunteers and in conditions
associated with a chronic elevation of endogenous cortisol
levels, for example Cushing’s disease (Starkman et al 2001;
Forget et al 2002), which is also associated with a high
incidence of depression that notably resolves with correction
of the hypercortisolemia (Dorn et al 1997). Patients receiving
systemic corticosteroid therapy also often exhibit cognitive
impairment and, in some instances, symptoms of
(hypo)mania, depression, and psychosis (Brown and
Chandler 2001). HPA axis dysregulation therefore has been
suggested to be one of the principal causes of both low mood
and neurocognitive impairment, possibly through inter-
actions with other neurotransmitter system (McAllister-
Williams et al 1998; Porter et al 2004).
The known consequences of hypercortisolemia on
neurocognitive function and mood, and the central role of
corticosteroid receptors in HPA axis regulation, therefore
indicate a possible use for antiglucocorticoid drugs and make
the GR specifically a potentially viable target for therapeutic
intervention.
Mifepristone (RU-486)
Discovery and development
Mifepristone (or RU-486) is a synthetic steroid with both
antiprogesterone and antiglucocorticoid properties. The
compound is a 19-nor steroid with substitutions at positions
C11 and C17 (17 beta-hydroxy-11 beta-[4-dimethylamino
phenyl] 17 alpha-[1-propynyl]estra-4,9-dien-3-one) which
antagonizes cortisol action competitively at the receptor level
(Nieman et al 1985). It was discovered in the early 1980s
by the French pharmaceutical company Roussel–Uclaf
(Herrmann et al 1982; Jung-Testas and Baulieu 1983). At
present it is licenced in the UK for the medical termination
of pregnancy (trade name: Mifegyne
®; marketing
authorization holder: Exelgyn Laboratories, Paris, France).
Mifepristone was the first antiprogestin to be developed and
it has been evaluated extensively for its use as an
abortifacient. The original target for the research group,
however, was the discovery and development of compounds
with antiglucocorticoid properties (Hazra and Pore 2001),
and it is these properties that are of greatest interest for their
application in the treatment of severe mood disorders and
psychosis.
Pharmacokinetics and
pharmacodynamic activity
The pharmacokinetics of mifepristone are dose-dependent
in humans (Ashok et al 2002). Due to saturation of the
serum-binding capacity, high-dose mifepristone results in
nonlinear kinetics, whereas lower doses show a linear pattern
(Leminen et al 2003). For example, following administration
of doses of  50–800 mg, after the absorption and distribution
phase of approximately 4–6 hours, the serum concentration
of mifepristone remains in the micromolar range for the
next 24–48 hours. Within the dose range of 2–25 mg, serum
concentrations of mifepristone, as well as the areas under
the concentration–time curves (AUC), increase according
to dose (Sitruk-Ware and Spitz 2003).
Following a single oral dose of 600 mg mifepristone,
the binding equivalent is present in measurable
concentrations 7 days after administration, only decreasing
below assay detection limits > 7–14 days (Foldesi et al 1996).
In this study, the concentration of the mifepristone bindingNeuropsychiatric Disease and Treatment 2006:2(1) 36
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equivalent reached a peak within approximately 2 hours
(doses 200–600 mg), indicating rapid absorption. Peak levels
were significantly greater following the 600 mg dose
(Cmax = 12.3 µmol/L vs 200 mg: 6.30 µmol/L), while the
bioavailability as assessed by the AUC was significantly
greater following 600 mg dose than both 200 and 400 mg.
These were not, however, directly proportional to the dose
increase (Foldesi et al 1996).
In contrast to mifepristone plasma concentrations,
plasma concentrations of its metabolites do increase in a
dose-dependent manner when larger
 doses are administered,
so that serum metabolite concentrations are close to, or even
in excess of, those of the parent compound (Lahteenmaki
et al 1987). These metabolites have some antiprogestin
and antiglucocorticoid properties, and therefore may
mediate some of the
 actions of mifepristone (Spitz and
Bardin 1993).
Side effects of chronic mifepristone
administration
Laue and colleagues reported that in healthy male normal
volunteers who received mifepristone (10 mg/kg/day), 8 of
11 subjects developed generalized exanthem after 9 days.
One subject developed symptoms and signs consistent with
the diagnosis of adrenal insufficiency (Laue et al 1990).
For immune function, it was reported that total white blood
cell counts, absolute lymphocyte, neutrophil, and eosinophil
counts, erythrocyte sedimentation rate, and quantitative
immunoglobulins did not change. Similarly, T-, B-, and
natural killer cell subsets did not change during treatment.
Furthermore, functional evaluation of lymphocyte
cytotoxicity and proliferation revealed no changes.
A study using lower doses (200 mg/day for 2 to > 31
months) in 14 patients with unresectable meningiomas
reported milder side effects. Most commonly, fatigue was
noted in 11 of the 14 patients (Grunberg et al 1991).
However, in a study of mifepristone (200 mg/day for up to
8 weeks) in chronic depression, 1 of 4 patients discontinued
treatment prematurely because of the appearance of a rash
(Murphy et al 1993). In patients with psychotic depression
receiving mifepristone (50–1200 mg/day for 7 days), 2 of
10 patients in the 600-mg group and 1 of 9 in the 1200-mg
group reported uterine cramping, while 1 of 11 patients in
the 50-mg group and 1 of 9 patients in the 1200-mg group
(but none in the 600-mg group) reported a rash. In both
cases, this had abated 1–2 months after study completion
(Belanoff et al 2002).
Antiglucocorticoid effects of
mifepristone
A large amount of human clinical data on the anti-
glucocorticoid actions of mifepristone have come from
studies in Cushing’s disease (Sartor and Cutler 1996).
Nieman and colleagues administered mifepristone orally at
increasing doses of 5, 10, 15, and 20 mg/kg/day for a
9-week period to a patient with Cushing’s syndrome due to
ectopic ACTH secretion. Following treatment, the somatic
features associated with Cushing’s syndrome ameliorated
and blood pressure normalized. Importantly, suicidal
ideation and depression also resolved, and all biochemical
glucocorticoid-sensitive parameters normalized (Nieman et
al 1985).
Mifepristone has also been shown to rapidly reverse
acute psychosis in Cushing’s syndrome (van der Lely et al
1991). More recently, high-dose (up to 25 mg/kg/day), long-
term mifepristone administration was shown to normalize
all biochemical glucocorticoid-sensitive measurements, as
well as significantly reverse psychotic depression in a patient
with Cushing’s syndrome caused by an ACTH-secreting
pituitary macroadenoma (Chu et al 2001). Although the
adrenal axis also normalized, the 18-month-long
mifepristone treatment course led to the development of
severe hypokalemia (attributed to excessive cortisol
activation of MRs), which responded to spironolactone
administration.
Use of mifepristone in mood
disorders and psychosis (Table 1)
Early work highlighted the potential for antiglucocorticoid
strategies in depression. Initially the focus of studies utilizing
mifepristone was on the effect on endocrine parameters
(Kling et al 1989; Krishnan et al 1992). In the first open
trial of mifepristone treatment of major depression, Murphy
and colleagues administered mifepristone (200 mg each
morning) for as long as it was tolerated, for up to 8 weeks
to 4 patients with “drug-resistant” depression. Data were
presented as a case-series and showed improvements of
between 16% and 66% on the Hamilton Depression Rating
Scale (HDRS) (Murphy et al 1993). The trial terminated,
however, due to problems obtaining the trial medication (the
supplier cancelled the contract).
Recent studies have renewed interest in the potential
therapeutic efficacy of GR antagonists in the treatment of
mood disorders and psychosis.Neuropsychiatric Disease and Treatment 2006:2(1) 37
Mifepristone for depression and psychosis
Table 1 Studies of glucocorticoid receptor antagonists in mood disorders and psychosis (see text for further details)
Effects on
Study Patient Concomitant Effects on neurocognitive
Study Drug Dose design N group medications symptoms function
(Kling et al Mifepristone 10 mg/kg
aExperimental 8 MDD Drug-free (2 weeks) n/a n/a
1989) single dose
(Krishnan et al Mifepristone 400 mg
aExperimental 7 MDD Drug-free (1 week) n/a n/a
1992) single dose
(Murphy et al Mifepristone 200 mg/day, Open-label 4 MDD Drug-free; HDRS scores decreased n/a
1993) up to benzodiazepines and between 16% and 66%
8 weeks acetaminophen for all patients.
permitted
(Høyberg et al ORG34517 150– Double-blind, 142 MDD Drug-free; All groups improved. n/a
2002) 300 mg/day, randomized, benzodiazepines Larger improvement
450– paroxetine permitted from baseline in low-
600 mg/day, controlled dose ORG group at day
up to 4 10. Patients reaching full
weeks remission significantly
higher in low- than both
the high-dose and
paroxetine-treated
groups (39.1% vs 20.5%
and 31.0% respectively).
(Belanoff et al Mifepristone 600 mg/day, Double-blind, 5 Psychotic Antipsychotic free (3 HDRS scores declined n/a
2001) 4 days placebo MDD days); benzodiazepines during mifepristone
controlled, and acetaminophen treatment in all patients.
crossover permitted BPRS scores declined in
4 of 5 patients.
(Belanoff et al Mifepristone 50, 600, Open-label 30 Psychotic Stable for 1 week HDRS response by dose n/a
2002) 1200 mg/day, MDD prior in 2/11 (18.2%) 5/10,
7 days (50%), 3/9 (33%) patients
respectively. BPRS
response in 4/11 (36.4%),
7/10 (70%), 6/9 (66.7%)
respectively.
(Simpson et al Mifepristone 200 mg tid, Open-label 20 Psychotic Drug-free (1 week) CGI and HDRS improved n/a
2005) 6 days MDD except for lorazepam after week 1, and
between week 1 to 4.
BPRS improved after
week 4
(Young et al Mifepristone 600 mg/day, Double-blind, 20 Bipolar Stable for 6 weeks HDRS (5.1 points), SWM improved
2004) 7 days placebo disorder prior MADRS (6 points), 19.8% over
controlled (depressed) BPRS (4 points) placebo at day 21.
RCT improved from baseline Spatial recognition,
at day 14 with active verbal fluency
drug. improved from
baseline following
active drug.
(Gallagher et al Mifepristone 600 mg/day, Double-blind, 20 Schizo- Stable for 6 weeks No effect on BPRS or No effect
2005) 7 days placebo phrenia prior Calgary. Improvements in
controlled (chronic, HDRS and MADRS in
RCT sympto- both arms of the study
matic) (nonspecific effect).
a These studies examined HPA axis responses only.
Abbreviations: BPRS, Brief Psychiatric Rating Scale; Calgary, Calgary Depression Scale; CGI, Clinical Global Impression; HDRS, Hamilton Depression Rating Scale;
HPA, hypothalamic–pituitary–adrenal; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; n/a, not assessed; RCT, randomized
clinical trial; SWM, Spatial Working Memory (CANTAB); tid, three times daily.Neuropsychiatric Disease and Treatment 2006:2(1) 38
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Psychotic depression
In a double-blind, placebo-controlled crossover case-series
in 5 patients with psychotic depression, Belanoff and
colleagues found a rapid improvement in depression ratings
and psychotic symptoms following 4 days’ treatment with
mifepristone (Belanoff et al 2001). Subsequently they have
replicated these findings in an open-label study in 30
psychotic depressed patients (Belanoff et al 2002). Patients
received mifepristone, either 50 mg/day (n = 11), 600 mg/day
(n = 10), or 1200 mg/day (n = 9) for 7 days. Criteria for
response were defined as a 50% reduction on the Hamilton
Rating Scale for Depression-21 (HAMD-21), a 30%
reduction on the Brief Psychiatric Rating Scale (BPRS), and
a 50% reduction on the BPRS positive symptom subscale.
Using these criteria, respectively, it was found that 18.2%,
36.4%, and 27.3% of patients responded to 50 mg/day; 50%,
70%, and 60% responded to 600 mg/day, and 33%, 66.7%,
and 66.7% responded to 1200 mg/day. The results of this
study also suggested that high-dose treatment (≥ 600 mg)
for short periods (≤ 7 days) was the optimal method of
administration.
A second trial has been carried out recently with a longer
follow-up period (Simpson et al 2005). Twenty MDD
patients (with psychotic features) were treated with
mifepristone 200 mg 3 times daily, open-label for 6 days.
All patients had been psychotropic medication-free (except
lorazepam for sleep) for at least 1 week prior to baseline
ratings. Significant improvements in HDRS and Clinical
Global Impression (CGI) scores were observed in the group
(from baseline) after 1 week and between weeks 1 and 4.
This effect remained stable to follow-up at 8 weeks. BPRS
scores also improved after week 4. A number of patients
did not complete the trial, however, because of good clinical
response (discharged and lost to follow-up) or nonresponse
(alternative clinical intervention required).
Preliminary communications have also been made on
the results of larger trials (n > 200) of mifepristone in
psychotic depression (Belanoff and DeBattista 2004;
DeBattista and Belanoff 2004). These studies suggest that
the effect on psychotic symptoms, particularly, may be rapid
and persistent. The publication of these results is awaited
and will provide clearer data on the efficacy of GR
antagonists in this condition.
Bipolar disorder
We have recently completed the first proof-of-concept study
on the use of GR antagonists in the treatment of bipolar
depression, in a double-blind, placebo-controlled crossover
design (Young  et al 2004). We hypothesized that
mifepristone (administered adjunctively to existing
medication) would improve neurocognitive function and
attenuate depressive symptoms in this disorder. Twenty
patients, ages 18 to 65, with a diagnosis of bipolar depression
(confirmed using the Structured Clinical Interview for DSM-
IV; SCID [First et al 1995]) and residual depressive
symptoms were recruited. Patients’ medication had been
unchanged for 6 weeks prior to participation and remained
so throughout the study period.
On the basis of previous research, it was predicted that
the principal cognitive domains that would be most sensitive
to changes in HPA axis function were working memory and
verbal declarative memory. Neurocognitive tests were
therefore administered to explore these domains. Following
treatment with mifepristone, selective improvement in
neurocognitive functioning was observed. Spatial working
memory performance was significantly improved compared
with placebo (19.8% improvement over placebo). Measures
of verbal fluency and spatial recognition memory also
significantly improved from baseline levels after
mifepristone. No significant change occurred after placebo.
Beneficial effects on mood were found; HDRS scores
were significantly reduced compared with baseline (mean
reduction of 5.1 points) as were Montgomery–Åsberg
Depression Rating Scale scores (mean reduction of 6.05
points). No significant change occurred after placebo.
Furthermore, baseline cortisol output correlated positively
with the percentage improvement in spatial working memory
error rate following mifepristone administration.
Schizophrenia
Utilizing the same experimental design as described above
(Young et al 2004), we have recently completed the first
trial to examine the efficacy of adjunctive mifepristone
administration in schizophrenia (Gallagher et al 2005). In
contrast to the findings on bipolar disorder, mifepristone
had no significant effect on symptoms or neurocognitive
functioning despite a pronounced effect on the HPA axis.
There are several possible explanations for this discrepancy.
As described above, mifepristone has been shown to have
some positive effects on depressive symptoms in bipolar
disorder as well as on psychosis in psychotic major
depression. Also, the effects of mifepristone were more
pronounced on neurocognitive function in bipolar patients.
This may suggest that affective symptoms or affectiveNeuropsychiatric Disease and Treatment 2006:2(1) 39
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psychosis may be modulated primarily by the HPA axis and
that neurocognitive dysfunction in mood disorders is steroid-
dependent and a consequence of HPA axis dysregulation,
whereas in schizophrenia these may be attributable to
different underlying neurobiological abnormalities.
Alternatively, it may be that the schizophrenic patients
recruited in this study did not have an abnormal HPA axis
at baseline. There is some evidence that the chronicity of
psychotic illness directly affects the neurobiology of the
HPA axis. Pariante and colleagues (2004) found that first-
episode psychosis was associated with a larger pituitary
volume, which was suggested to be a consequence of
activation of the HPA axis. In “established” schizophrenia
(such as in the population in our study), smaller pituitary
volume was observed (Pariante et al 2004b). Therefore, the
schizophrenic patients may not respond to a GR antagonist
in the same manner as patients with affective illnesses.
Other GR antagonists
ORG 34517 was designed as a specific antiglucocorticoid
to selectively target the GR. A preliminary report comparing
low- and high-dose ORG 34517 administration and
paroxetine found that all treatment groups showed
improvements in HDRS scores over the 4-week treatment
period (Høyberg et al 2002). Low-dose ORG 34517
appeared to increase the speed of response, however, HDRS
scores being significantly lower (from baseline) than both
other treatment arms by day 10 of the trial. This effect was
greater in subjects with a higher degree of HPA axis
dysfunction. The proportion of subjects in full remission
by the end of the trial was also significantly greater than the
proportion of both the high-dose and paroxetine-treated
groups (39.1% vs 20.5% and 31.0% respectively).
Mechanisms of action
Corticosteroid receptor imbalance
The mechanism through which mifepristone may be exerting
effects on symptoms and neurocognitive function is unclear.
It has been suggested that by blocking the GR a “resetting”
of the HPA axis may occur (Belanoff et al 2002).
Interestingly, animal work has shown that in comparison
with other selective GR antagonists, mifepristone was the
only compound to increase GR binding in the frontal cortex,
although an increase in MR binding was also observed
(Bachmann et al 2003). In the neocortex, however,
mifepristone selectively decreased MR binding.
GR integrity has consistently been shown to be lowered
in patients with severe psychiatric disorders both
functionally, using the DST (Rush et al 1996), and
structurally, with reduced GR mRNA expression in post-
mortem brain tissue samples (Webster et al 2002). There is
some evidence, however, that MR function may be normal
or even enhanced in mood disorders (Young et al 2003).
Although speculative, some of the therapeutic actions of
mifepristone may operate through the ability of the drug to
modulate corticosteroid receptor balance (ie, exposing brain
MR to the elevated cortisol levels caused by GR blockade).
This may be particularly so for neurocognitive functioning,
which depends on the relative ratio of corticosteroid receptor
occupancy (Lupien and McEwen 1997).
Transport of cortisol into the brain
Recent work has shown that many antidepressant drugs have
actions on blood-brain barrier steroid transporters (such as
multidrug resistance p-glycoprotein). Plasma cortisol cannot
freely enter the brain by passive diffusion because its access
is limited by such membrane steroid transporters which
actively expel cortisol from the brain. It has been suggested
that some antidepressants may inhibit membrane steroid
transporters at the blood–brain barrier and in neurones, so
that more cortisol is able to enter the brain (Pariante 2004;
Pariante et al 2004a), thereby restoring glucocorticoid-
mediated negative feedback of the HPA axis (Pariante et al
2004a). Hypercortisolemia is therefore argued to be a
possible compensatory adaptive response to a central
hypocortisolemic state (Pariante 2003). Considering
mifepristone: the antagonist action of mifepristone on GR
causes a robust (2- to 3-fold) elevation in cortisol levels and
this may facilitate HPA axis negative feedback. Certainly,
this may be the case when mifepristone is administered
adjunctively with other antidepressant medications (see
above). This mechanism may underlie some of the clinical
benefits of the drug.
Speed of response
One notable characteristic of antiglucocorticoid strategies
in studies to date is that they appear to initiate a rapid, short-
term clinical response. The study of the ORG 34517 by
Høyberg and colleagues in medication-free patients with
major depression showed that differences between treatment
arms emerged after day 7 of the trial, with significant benefits
being observed at day 10–14. This was especially
pronounced in patients with clearly defined HPA axisNeuropsychiatric Disease and Treatment 2006:2(1) 40
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abnormalities. After this time, response rates were
approximately equivalent (Høyberg et al 2002). Rapid
responses have also been observed following mifepristone
administration in psychotic depression (Belanoff et al 2001;
Belanoff et al 2002; Simpson et al 2005).
Alternative antiglucocorticoid strategies such as cortisol
synthesis inhibition similarly alter the course of clinical
response. Jahn and colleagues administered metyrapone or
placebo to 63 (psychotropic) medication-free patients with
major depression. A higher proportion of patients receiving
metyrapone showed a positive treatment response, but
importantly the response began within a week of initiation
of treatment, suggesting an earlier onset of action (Jahn et
al 2004).
The ability of such drugs to rapidly improve treatment
response suggests that they may be used either to increase
efficacy of treatment regimens in medicated patients or
initiate a response that can be maintained with conventional
treatments. The optimum strategy for the clinical application
of GR antagonists has yet to be established, with their
potential role as either first-line or adjunctive treatments
being unclear.
Effects on neurocognitive function
Although few studies to date have examined the neuro-
cognitive effects, mifepristone may be efficacious in this
respect in mood disorder.
In a recent study in rats, mifepristone was the only GR
antagonist examined to increase both MR and GR binding
in the frontal cortex (Bachmann et al 2003). This may
underpin the selective pattern of improvement in neuro-
cognitive function seen in our study (Young et al 2004),
which was restricted to tests that have been shown to be
sensitive to frontal lobe dysfunction. Oitzl and colleagues
have shown that mifepristone (RU-38486) injected locally
into the dorsal hippocampus dose-dependently improved
the performance of male Wistar rats in the water maze 24
hours after treatment (Oitzl et al 1998a). Importantly,
opposing effects on spatial memory have been shown to
occur after either phasic or continuous blockade of brain
GR by intracerebroventricular administration of
mifepristone. Phasic blockade was found to dose-
dependently impair spatial memory (Morris water maze),
examined after a daily pretraining administration, whereas
continuous GR blockade resulted in a long-lasting
facilitation of spatial performance (Oitzl et al 1998b). In
humans, aspects of spatial memory are affected in various
degrees in patients with hippocampal lesions (Kessels et al
2001), some tasks such as (spatial) working memory being
more dependent on the integrity of the frontal lobes (Owen
et al 1995; Owen et al 1996; Kessels et al 2000; Kessels et
al 2001). Consequently, the effects of mifepristone on
corticosteroid receptor expression may explain the observed
pattern of neurocognitive improvement observed in studies
to date.
Neuroprotection
The potential neuroprotective actions of mifepristone have
been demonstrated preclinically. Mifepristone was found
to protect rat primary hippocampal neurons, clonal mouse
hippocampal cells, and organotypic hippocampal slice
cultures against oxidative stress-induced neuronal cell death
induced by amyloid beta protein, hydrogen peroxide, and
glutamate (Behl et al 1997). Interestingly, this effect was
independent of the presence and activation of glucocorticoid
or progesterone receptors. Other studies have also
subsequently demonstrated neuroprotective effects of
mifepristone (Ghoumari et al 2003), although the precise
mechanism through which these actions are exerted is
unclear. Nevertheless, these actions may be of therapeutic
benefit.
Conclusions and future directions
The use of mifepristone and other GR antagonists in the
treatment of mood disorders and psychosis is very much at
the proof-of-concept stage. Results are encouraging and
several larger-scale clinical trials are underway to better
establish the clinical utility of this class of drug. Drugs
targeting other facets of the HPA axis, such as CRH-1-
receptor antagonists and vasopressin-1b-receptor
antagonists, are also being examined (Zobel et al 2000;
Holmes et al 2003; Kunzel et al 2003), as well as the
application of GR antagonists in the treatment of mood
symptoms and cognitive impairment in neurological
disorders such as Alzheimer’s disease (Pomara et al 2002).
Several important questions remain to be answered,
including how long the treatment effects persist and the
optimal method of administration, ie, continuous or repeated,
short-term administrations. These data will provide valuable
information on the overall efficacy and safety of this class
of treatment (see Mackin et al 2005) and may ultimately
lead to the development of specific antiglucocorticoid
compounds for use in severe psychiatric illness.Neuropsychiatric Disease and Treatment 2006:2(1) 41
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